Vesilute

Lys-Glu-Asp-Pro, KEDP, Везилют; sometimes confused with Vesugen (Lys-Glu-Asp, the "vascular" tripeptide)

Immune & bioregulators

Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

Summary

Class: Synthetic tetrapeptide (four amino acids) from the Khavinson "peptide bioregulator" family, assigned by its developers to the bladder
Mechanism: Proposed, by analogy with the rest of the family, to enter bladder-wall cells and modulate gene expression toward normal tissue function and repair; no published experiment demonstrates this for Vesilute itself
Routes studied: None published. Community: oral capsules or sublingual; occasionally subcutaneous
Dose range reported: No literature doses. Community-reported: 1–10 mg/day for 10–20 days per "course", repeated two or three times a year, following the general pattern for Khavinson peptides
Half-life: Not characterised. Short charged peptides of this type are expected to be degraded within minutes in blood and largely digested if swallowed
Storage: Capsules: room temperature, dry. Lyophilised powder: refrigerate, protect from light. Reconstituted: refrigerate, use within ~4 weeks (community practice)
Regulatory status: Not approved as a medicine anywhere. Sold in Russia as a dietary supplement / parapharmaceutical †

Doses are as reported in studies or by the community — never recommendations.

1What it is

Vesilute is marketed as the bladder member of the Khavinson family of short synthetic peptides developed at the St Petersburg Institute of Bioregulation and Gerontology. The family's premise is that each tissue has a short peptide that "regulates" it: Epitalon for the pineal gland, Cortagen (#94) for the cortex, Cardiogen for the heart, Vesugen for blood vessels, and so on. Vesilute (Lys-Glu-Asp-Pro) is Vesugen (Lys-Glu-Asp) with a proline added, and it is aimed at the urinary bladder — typically promoted for age-related bladder symptoms, urgency and recurrent cystitis.

This profile has to say something uncomfortable plainly: we could not identify a single peer-reviewed study — in any language, in animals or in people — that tests Vesilute specifically. The originating group has published on several of its peptides (Epitalon, Vilon, Livagen, Cortagen, Vesugen, Bronchogen) in Bulletin of Experimental Biology and Medicine and in its own monographs, and has described bladder-targeted peptides in patents and product literature, but Vesilute itself does not appear to have a primary publication we can cite with confidence. The literature is not thin; for this compound it is, as far as we can tell, absent. Everything below is therefore family-level reasoning, clearly labelled, and community anecdote.

2How it's thought to work

The originating group's general model for all its short peptides, not demonstrated for Vesilute:

Cell and nuclear penetration. Charged tetrapeptides are proposed to pass through cell membranes and into the nucleus, where they bind specific DNA sequences or histone proteins and alter gene transcription (Khavinson 2011).

Tissue specificity. Each peptide is said to preferentially affect the organ it was derived from — a claim resting on amino-acid composition analysis of organ extracts and on molecular modelling, not on tracer or distribution studies.

"Normalising" effect. The group reports its peptides restore protein synthesis and cell proliferation in aged or damaged tissue and reduce inflammatory and apoptotic markers.

For the bladder. Mechanistically one would expect claims about urothelial repair, detrusor (bladder muscle) function and local inflammation. None has been published for Vesilute.

Proposed: a cosmetic peptide aimed at leaky microvessels under the eye, where the discolouration is largely blood that has already escaped and the iron left behind as it breaks down. Holding the vessels shut is the stated mechanism; the evidence is limited.Schematic — not to scale

3What the research shows

Any outcome for Vesilute specifically

No identifiable published study, animal or human.

Khavinson family, gene-regulation and cell-culture work

and modelling studies describe short peptides binding DNA, altering gene expression and promoting proliferation or differentiation in cultured cells (Khavinson 2011; reviews 2020–2021). Relevant to the premise, not to the bladder. [1]

Graded C/B

Khavinson family, animal and clinical studies of other peptides

Rodent studies and small, mostly open-label Russian clinical reports exist for Epitalon, Vilon, Livagen, Cortagen and others. Their quality is covered in the respective profiles. They do not transfer evidence to Vesilute; a different sequence is a different compound.

Bladder symptoms

Community reports mention reduced urgency, fewer night-time trips to the bathroom and fewer cystitis episodes after a course. Bladder symptoms fluctuate and respond strongly to attention and hydration changes, so uncontrolled reports here carry very little weight.

4Reported side effects and interactions

Literature-reported

none exists for Vesilute. The family is described by its developers as non-toxic in rodent testing.

Community-reported

essentially nothing beyond occasional mild gastrointestinal discomfort from capsules; most users report no noticeable effects of any kind, positive or negative.

Theoretical. a peptide promoted as stimulating cell proliferation in the bladder lining carries a theoretical caution for anyone with a history of bladder cancer or with unexplained haematuria (blood in urine), which should always be investigated by a clinician before anything else is tried. Oral tetrapeptides are expected to be largely digested, so the realistic risk and the realistic benefit of capsules are both likely to be low.

Interactions. none established.

Markers researchers commonly monitor

No compound-specific markers exist. For anyone tracking bladder symptoms while taking it:

Marker	Why it's watched
A bladder diary (voids per day and night, urgency episodes, fluid intake) for a week before and during	the only honest outcome measure for the claimed effect, and one that also reveals how much symptoms vary on their own.
Urinalysis and urine culture	recurrent cystitis is a medical problem with standard tests; a peptide course should not delay them, and haematuria must be investigated.
Creatinine/eGFR	basic kidney function baseline if urinary symptoms are the concern.
CBC and CMP	general baseline for a compound with no human safety literature.

Free for everyone. Safety information is never behind a paywall.

5Reconstitution and handling

Sold mainly as oral capsules (typically 10–20 mg per capsule, labelled as a supplement in Russia) and occasionally as powder. Injectable use is a community extrapolation with no published basis in any species. If , use and refrigerate. The calculator can handle it, but the honest note is that there is no dose from any study to calibrate against.

Open in calculator, pre-loaded →

6Commonly studied alongside

"Studied" is too strong; it is "used alongside" other Khavinson peptides in sequential courses — Vesugen (vessels), Cortagen (#94), Epitalon, Cardiogen, Chonluten, Testagen or Ovagen — and sometimes with Cerebrolysin or Thymogen in Russian practice. No combination has any data.

Informational cross-links. Not stack recommendations.

7Regulatory status by region

Region	Status (checked —)
United States	Not FDA-approved; not a lawful dietary ingredient; not on the Category 2 compounding list to our knowledge †
European Union	Not authorised as a medicine or food supplement ingredient
United Kingdom	Not licensed
Australia	Not approved
South Africa	Not registered
Russia	Sold as a dietary supplement / parapharmaceutical, not a registered medicine †
Sport (WADA)	Not specifically listed; non-approved substances fall under S0 †

8Open questions

Does any primary study of Vesilute exist? If a reader can point to one, this profile should be revised.
Does an oral tetrapeptide reach the bladder wall intact in humans? No pharmacokinetic data for any peptide in the family.
Independent replication of the family's gene-regulation model in living tissue.

9References

1Khavinson VKh et al. (2011). Short cell-penetrating peptides: a model of interactions with gene promoter sites. Bull Exp Biol Med. PubMed
2Khavinson VKh, Malinin VV (2005). Gerontological Aspects of Genome Peptide Regulation. Karger (monograph). PubMed
3Khavinson V et al. (2021). Peptide regulation of gene expression: a systematic review. Molecules [verify]. PubMed · DOI
4Khavinson VKh (2002). Peptides and ageing. Neuro Endocrinol Lett (supplement) [verify]. PubMed

References are being resolved to PubMed/DOI identifiers; links search PubMed for the citation until then.

† Being confirmed by our reviewers against current sources.

10Community

forum threads →

community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

26 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.